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A peptide targeted contrast agent, CLT1-(Gd-DTPA), was synthesized for molecular imaging of ﬁbronectin-ﬁbrin
complexes in tumor tissue with magnetic resonance imaging (MRI). The T1 and T2 relaxivities of CLT1-(Gd-
DTPA) were 4.22 and 4.45 mM
-1 s
-1 at 3 T, respectively. The targeted contrast agent speciﬁcally bound to
tumor tissue and resulted in signiﬁcant tumor contrast enhancement at a dose of 0.1 mmol Gd/kg for at least 60
min in mice bearing HT-29 human colon carcinoma xenografts as shown in dynamic MR images. In contrast, a
control nontargeted contrast agent, Gd(DTPA-BMA), was cleared rapidly with little tumor enhancement 60 min
postinjection. Tumor enhancement with CLT1-(Gd-DTPA) was signiﬁcantly reduced after coinjection with a
3-fold excess of free CLT1 peptide. The preliminary study has shown that CLT1-(Gd-DTPA) can speciﬁcally
bind to the ﬁbrin-ﬁbronectin complexes in tumor tissues, resulting in signiﬁcant tumor enhancement. The targeted
contrast agent has a potential for cancer molecular imaging with MRI.
Magnetic resonance imaging (MRI) is a powerful imaging
modality for morphological and functional imaging. MRI
provides anatomical images of soft tissues with high spatial
resolution and is effective for noninvasive imaging of physi-
ological properties, e.g., diffusion, perfusion, and vascularity,
of the tissues of interest (1). However, MRI has not been
effectively used for molecular imaging because of its low
sensitivity. The direct conjugation of targeting agents, e.g.,
peptides, antibodies, and proteins, to clinical MRI contrast
agents, e.g., Gd(III) chelates, could not deliver a sufﬁcient
amount of contrast agents for MRI to effectively detect the
molecular targets expressed on the surface of cells of
interest (2, 3). Consequently, a large number of Gd(III) chelates
have been incorporated into various targeted nanoparticles for
MR molecular imaging to increase local concentration of
contrast agents (4-8). Unfortunately, the size of these nano-
particles is much larger than the renal ﬁltration threshold (ca.
4.5 nm), and they cannot be readily excreted from the body.
Long-term tissue retention of high-dose Gd(III) based contrast
agents may also cause toxic side effects such as systemic
nephrogenic ﬁbrosis (9, 10).
The limitations of MRI for molecular imaging can be
overcome by proper selection of molecular biomarkers and using
agents that can be readily excreted (11). Stable Gd(III) chelates
have been proven safe in patients except those with intermediate
and late-stage renal diseases. Since the amount of biomarkers
expressed on the cell surface may not be sufﬁcient for molecular
imaging with MRI, other biomarkers with high local expression
can be used for MR molecular imaging. It has been reported
that tumor stroma have a unique meshwork of clotted plasma
proteins that are not present in normal tissues (12, 13). The
presence of the ﬁbrin in tumor meshwork is known to associate
with increased microvessel permeability in neoplastic tissues
(12), and ﬁbronectin in tumor stroma is also associated with
tumor angiogenesis (13). The clotted plasma proteins might be
attractive targets for molecular imaging with MRI. Recently,
Ruoslahti and colleagues have identiﬁed peptides, including
CLT1 and CLT2 peptides, which can speciﬁcally bind to the
ﬁbronectin-ﬁbrin clots in various tumor tissues with little
nonspeciﬁc binding to normal tissues (14). The incorporation
of such peptides to Gd(III) chelates may result in targeted
contrast agents for speciﬁc tumor imaging with MRI. As
compared to nanoparticulate targeted contrast agents, the small
molecular targeted contrast agents can rapidly diffuse into tumor
tissue and bind to tumor meshwork. The unbound contrast agents
can be rapidly excreted from the body via renal ﬁltration.
Consequently, signiﬁcant signal enhancement of molecular
targets can be visualized by MRI with minimal nonspeciﬁc
background enhancement.
Here, we report a targeted contrast agent, a conjugate of a
cyclic decapeptide CGLIIQKNEC (CLT1) and Gd-DTPA, for
MR molecular imaging of ﬁbrin-ﬁbronectin complexes in
tumor tissues. The peptide CLT1 was ﬁrst synthesized using
standard solid-phase peptide synthesis from Fmoc-protected
amino acids (15) on a 2-chlorotrityl chloride resin. At the end
of the peptide synthesis, an excess of DTPA dianhydride in
DMSO was reacted with the peptide on the beads at room
temperature for4ht oconjugate DTPA at the N-terminal of
the peptide. The resin was completely washed with water, DMF,
dichloromethane, and methanol three times each. The CLT1-
DTPA was then removed from the resin using TFA solution
(TFA 94%, 1,2-ethanedithiol 2.5%, triisobutylsilane 2.5%, water
1%). The product was exposed to air for about2ht oallow the
formation of disulﬁde bonds for the cyclic peptide and then
puriﬁed using preparative HPLC with a C18 column. CLT1-(Gd-
DTPA) was ﬁnally prepared by complexation of CLT1-DTPA
with Gd(OAc)3 at pH 6. Excess Gd(OAc)3 was removed by
precipitation at pH 11. The ﬁnal product was puriﬁed by
preparative HPLC. The mass (m/z,M+ H
+) of CLT1-(Gd-
DTPA) was 1650.75 (calcd 1650.2) as determined by MALDI-
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CLT1-(Gd-DTPA) were determined on a Siemens Trio 3T
scanner at room temperature using an inversion recovery (IR)
prepared turbo spin-echo (TSE) imaging pulse sequence and
a turbo spin-echo imaging sequence with turbo factor 3 (16),
respectively. The T1 and T2 relaxivities of CLT1-(Gd-DTPA)
were 4.22 and 4.45 mM
-1 s
-1 at 3 T. Figure 1 shows the
structure of CLT1-(Gd-DTPA) and the plots of the T1 and T2
water proton relaxation rates at various concentrations of the
contrast agent at 3 T.
In vivo molecular imaging of ﬁbrin-ﬁbronectin complexes
in tumor with the targeted contrast agent and MRI was evaluated
in female athymic nu/nu mice bearing HT-29 human colon
carcinoma xenografts with a T1-weighted 2D spin-echo se-
quence. A clinical contrast agent, Gd(DTPA-BMA), was used
as a control. Competitive targeting of free CLT1 peptide to
CLT1-(Gd-DTPA) was also studied with coinjection of
CLT1-(Gd-DTPA) and a 3-fold excess of free CLT1 peptide.
A group of 3 mice was used for each contrast agent. The mice
were anesthetized by intramuscular administration of a mixture
of ketamine (45 mg/kg) and xylazine (6 mg/kg) for MRI. The
CLT1-(Gd-DTPA) and Gd(DTPA-BMA) was intravenously
injected at a dose of 0.1 mmol/kg. Contrast-enhanced MR
images were acquired before and after injection at 1, 10, 30,
and 60 min on a Siemens Trio 3T scanner using a human wrist
coil. High-resolution 3D images were acquired with a 3D
FLASH sequence with 25° ﬂip angle, TR/TE ) 7.8/2.7 ms, slice
thickness 0.5 mm, ﬁeld of view (FOV) 120 mm, voxel size 0.5
× 0.5 × 0.5 mm
3. T1-weighted 2D axial tumor images were
acquired with a 2D spin-echo sequence with TR 400 ms, TE
10 ms, 90° tip angle, and FOV 50 mm. Mice were sacriﬁced
24 h postinjection, and tumor tissues were removed and ﬁxed
with 3% paraformaldehyde and embedded in parafﬁn. Tissue
sections (4 µm thickness) were incubated in 3% H2O2 for 10
min to block endogenous peroxidase activity and boiled in
antigen retrieval solution for 15 min in microwave. The sections
were then incubated with primary antibody overnight and
secondary antibody the next day for visualization using the ABC
kit (Santa Cruz Biotechnology).
Figure 2 shows the representative axial T1-weighted 2D
spin-echo images of the tumor tissues of the mice bearing HT-
29 tumor xenografts before and after injection of the contrast
agents. Signiﬁcant enhancement was observed in tumor tissues
for CLT1-(Gd-DTPA) 10 min postinjection, and strong en-
Figure 1. Chemical structure of CLT1-(Gd-DTPA) and plots of 1/T1
and 1/T2 versus the concentration of the contrast agent.
Figure 2. T1-weighted 2D spin-echo images of mice bearing HT-29
xenografts before contrast and at 10, 30, and 60 min postinjection of
CLT1-(Gd-DTPA), Omniscan and competitive mixture. Arrow points
to the tumor tissue.
Figure 3. Plots of CNR versus time in tumor periphery (A) and inner
area (B) before contrast and at 1, 10, 30, and 60 min postinjection of
CLT1-(Gd-DTPA), Omniscan, and competitive mixture.
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injection. For the competitive study, the tumor enhancement
with CLT1-(Gd-DTPA) was reduced after the coinjection of
free peptide, which indicates that the free peptide recognizes
the same binding site within tumor tissue as CLT1-(Gd-DTPA).
The control agent Gd(DTPA-BMA) did not show a strong tumor
enhancement as compared to CLT1-(Gd-DTPA).
MR signal intensity was also measured, and the contrast to
noise ratio (CNR) in the tumor tissues was calculated as CNR
) (SItissue - SImuscle)/SDnoise. Statistical analysis was perform
using two-way ANOVA. Figure 3 shows the CNR of the tumor
tissue in tumor periphery and inner areas before and at various
time points after injecting the contrast agents. CLT1-(Gd-
DTPA) showed higher CNR at 10 min after injection in the
tumor periphery area and decreased gradually. At the same time,
CNR in tumor inner area increased gradually during the period
of 60 min postinjection. The CNR in both tumor periphery and
inner tissue with Gd(DTPA-BMA) decreased rapidly after it
reached the maximum values at 1 min postinjection. The
CLT1-(Gd-DTPA) showed signiﬁcantly higher CNR than the
control Gd(DTPA-BMA) in tumor periphery since 10 min
postinjection (p < 0.05) and in the tumor inner area since 30
min postinjection (p < 0.05). The results indicate binding and
retention of the targeted contrast agent to tumor tissue. The
presence of free peptide resulted in signiﬁcant reduction of CNR
in both tumor periphery and inner tumor tissue (p < 0.05) except
at the point of 30 min postinjection. The result indicated that
the presence of free peptide inhibited the binding of the targeted
contrast agent to its target, resulting in decreased contrast
enhancement in tumor tissue.
The plasma proteins ﬁbrin(ogen) and ﬁbronectin play a
prominent role in hemostasis and wound healing. Fibrinogen is
activated to form an insoluble ﬁbrin clot following vascular
injury. The clot also serves as a provisional matrix for adhesion
and migration of cells or proteins including ﬁbronectin, which
is incorporated into the ﬁbrin clot upon ﬁbrin polymerization.
The presence of the ﬁbrin and ﬁbronectin in tumor meshwork
has also been reported in the literature due to the leakiness of
tumor vasculature (16, 17). CLT1 peptide was reported to
speciﬁcally bind the ﬁbrin-ﬁbronectin complexes in tumor
tissues (14). We further carried out immunohistochemical study
to verify the presence of ﬁbronectin in the HT-29 tumor tissues
after MR imaging. Figure 4 shows the immunostaining of
ﬁbronectin in HT-29 tumor tissues with (Figure 4A) or without
(Figure 4B) nucleus staining. The histochemical staining clearly
indicated the existence of ﬁbronectin in the extracellular spaces
of tumor tissues.
It is a challenge for MRI to detect in vivo molecular targets
with molecular imaging because of its low sensitivity. We have
shown here that MRI can be effective for molecular imaging if
suitable molecular targets are identiﬁed. The targeted contrast
agent CLT1-(Gd-DTPA) had little nonspeciﬁc binding and
accumulation in the normal tissue despite that the peptide was
hydrophobic. It bound to its molecular target in tumor tissue,
resulting in signiﬁcant and prolonged tumor enhancement. The
result was consistent to what was originally reported by
Ruoslahti et al. in other tumor models, which further conﬁrmed
that CLT1 peptide had a high speciﬁcity to ﬁbrin-ﬁbronectin
complexes in tumor stroma (14). Because of the high content
of the ﬁbrin-ﬁbronectin complexes in the tumor stroma, the
peptide was able to deliver a sufﬁcient amount of Gd-DTPA
chelates to the molecular targets to generate detectable signal
enhancement for MRI. Since the contrast agent was a low
molecular weight chelate with a small size, it was able to be
cleared rapidly from the blood circulation and normal tissues,
resulting in strong CNR in the tumor tissue.
MR molecular imaging of ﬁbrin-ﬁbronectin complexes in
tumor tissue with CLT1-(Gd-DTPA) also has the potential to
characterize tumor angiogenesis. It has been reported that the
presence of ﬁbrin in the tumor meshwork is associated with
increased microvessel permeability in neoplastic tissues (12),
and ﬁbronectin in tumor stroma is also associated with tumor
angiogenesis (13). The result suggested that CLT1-(Gd-DTPA)
was able to detect the presence of ﬁbrin-ﬁbronectin complexes
in the angiogenic tumor tissues. The correlation of ﬁbrin-ﬁbro-
nectin complexes to tumor angiogenesis may provide an
effective method for tumor angiogenesis imaging with MRI and
CLT1-(Gd-DTPA). Accurate assessment of tumor angiogenesis
is critical for tumor grading, assessment of tumor response to
anticancer therapies, particularly antiangiogenesis therapies, and
patient management.
Fibrin-ﬁbronectin complexes are also present in the plasma
clots of wounds and other pathologic tissues with leaky blood
vessels such as atherosclerotic plaques. Ruoslahti and colleagues
showed that ﬂuorescein-labeled CLT peptides speciﬁcally bound
to the injured blood vessel wall, not the intact arteries and tissues
(14). It suggests that MRI with CLT1-(Gd-DTPA) may have
broad applications, including molecular imaging of cancer,
angiogenesis, vascular integrity, and assessment of wound
healing, anthrosclerosis, and tumor response to antiangiogenesis
therapies. As compared to other targeting moieties, including
proteins, antibodies, and their fragments, the peptide targeted
Gd(III) chelate is advantageous for MR molecular imaging due
to its excellent tissue permeability and rapid clearance from
nonspeciﬁc tissue or organs.
In summary, a targeted contrast agent CLT1-(Gd-DTPA)
speciﬁc to ﬁbrin-ﬁbronectin complexes was prepared and
preliminarily evaluated in an animal tumor model for effective
Figure 4. Staining of ﬁbronectin in HT-29 tumor tissues with hemoxylin (A) or without hemoxylin (B) (40× magniﬁcation). Arrows point to the
stained ﬁbronectin (brown color) in the EES space, and blue in A indicates nuclus stained with hemoxylin.
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minimal nonspeciﬁc binding and accumulation in normal tissues.
CLT1 peptide was able to deliver a sufﬁcient amount of Gd-
DTPA chelates to its molecular target for effective molecular
imaging with MRI in tumor. CLT1-(Gd-DTPA) is a promising
targeted contrast agent for MR molecular imaging of ﬁbrin-ﬁbro-
nectin complexes. It has a great potential for cancer detection
and diagnosis, characterization of tumor angiogenesis, and
imaging wounds and atherosclerosis.
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